Background: Bivalirudin (Angiomax) has proven to be a valuable alternative to heparin in percutaneous coronary intervention (PCI). The aim of this study is to assess the efficacy and clinical safety of bivalirudin administration in patients undergoing PCI and vascular brachytherapy (VBT) with γ and β radiation. Methods: A total of 100 patients who were included in the BRAVES (Brachytherapy and Bivalirudin Evaluation Study) trial at the Washington Hospital Center, and who underwent PCI and VBT with either γ ( 192 Ir) or β ( 32 P or 90 Sr/Y) radiation were investigated for procedural, in-hospital and 30-day clinical outcomes. All patients were treated with bivalirudin as a single antithrombotic agent during PCI. Results: Baseline clinical and angiographic characteristics were similar between the two groups. In-hospital events showed a higher prevalence of early thrombotic occlusions in patients treated with γ radiation (25% vs.1.1%, p = 0.02) Thirty-day outcomes were comparable in both groups. Conclusions: The use of bivalirudin as an antithrombotic agent during PCI and vascular brachytherapy was safe only with β radiation, and should not be use be used in the setting of PCI and γ radiation due to high incidence of intracoronary thrombosis.
Background: There is significant controversy regarding troponin release after non-complicated percutaneous coronary interventions (PCI) with stent. Pathogenic mechanisms and predictive factors are not well characterized. We examined the relationship of this phenomenon with clinical, procedural, thrombotic and inflammatory factors. Methods:We prospectively studied patients undergoing PCI with stent excluding those with recent myocardial infarction (<14 days). Levels of C-Reactive Protein (CRP), Fibrinogen (F), Fibrin D-dimer (DD), Troponin I (TnI) and CK-MB were determined pre-PCI and 8 and 24 hrs post-PCI. Results: A total of 221 patients were included with 200 (90.5%) not presenting any periprocedural complication. Among the 200 non-complicated cases, 30 patients (15%) showed TnI elevation after PCI. We compared these 30 cases (group TnI+) with the remaining 170 without TnI elevation (group TnI-). Patients in group TnI+ were significantly older (69±8yrs vs 61±12yrs; P<0.05), had more diffuse lesions (60% vs 22%; P<0.05) and more lesions treated (1.85 ± 0.7 vs 1.45 ± 0.7; P<0.05). Basal and post-PCI levels of CRP and DD were significantly higher in group TnI+. Post-PCI increase in DD was significantly higher in TnI+ group (median 110mgr/ml vs 23mgr/ml; P<0.05). Logistic regression analysis showed as independent predictors for TnI increase the treatment of diffuse lesions, age >65 yrs, 2 or more lesions treated and a basal CRP>III cuartile. A strongly independent association was found between TnI increase and the post-PCI DD measurement (OR: 13; 95% CI, 4.4 to 37; P= 0.0001). The non-complicated group presented major cardiac events in 26 pts (13%) in a follow up of 11± 2 months. Only age >65 yrs, diabetes and treatment of diffuse lesions were independent predictors for events. Conclusions: 1) These findings suggests microthrombosis-embolization as the main mechanism for TnI elevation in non-complicated PCI. 2)This event was related with age over 65 years, treatment of multiple and diffuse lesions and high basal CRP levels. 3) The prognostic significance found in other studies may be explained by the association of this phenomenon with a more diffuse and aggressive disease.
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Predilatation Before Distal Protection Device Placement Is Associated With Increased Procedure-Related Background: Distal protection devices (DPD) have been shown to prevent embolization during saphenous vein graft (SVG) stenting. Although optimal to have DPD deployed during all phases of intervention, this may be impossible in cases in which device can't cross. We examined whether the need for balloon pre-dilatation (PD) prior to lesion crossing with the DPD impacts outcomes. Methods: In FIRE trial, 651 pts with SVG stenting were randomized to DPD with either the FilterWire EX (FW) or the balloon GuardWire (GW) system. When the operator was unable to cross lesion with DPD, PD with was allowed. Data regarding PD was available in 598 pts. Results: PD prior to DPD placement was required in 41 (6.9%) pts; 31 (10.2%) FW, and 10 (3.4%) GW (p=0.001). Compared to pts without PD, PD pts had smaller minimal luminal diameter (0.79 vs 1.1, p=0.01), higher diameter stenosis (71% vs 66%, p=0.01), and lower % of pts with baseline TIMI 3 flow (64% vs 84%, p<0.01). After PD, subsequent attempts to re-introduce the DPD were successful in 24 of 31 FW pts and 10 of 10 GW (77% vs 100%, p=0.1). Procedural and 30 day outcomes appear in the Table. Conclusions: Lesions which cannot be crossed by DPD without PD are more complex.
The necessity for PD is associated with increased rates of Q-wave MI and a trend toward increased MACE. These data emphasize the importance of establishing distal protection in SVGs before any intervention, and suggest that newer lower profile, more flexible and crossable devices may further improve the safety of intervention in SVGs. Background: Distal emboli following saphenous vein grafts (SVG) stenting results in high rates of peri-procedural events. Distal protection devices (DPD) were shown to be associated with improvement in outcomes. We compared the effect of balloon vs. filter devices on blood flow (frame count) and myocardial perfusion (blush). Methods: In two institutions, the first 57 consecutive pts that had filter-DPD SVG-stenting of de-novo lesions were compared to 57 consecutive pts in whom balloon -DPD was used, in the same period of time. Measurements were done before placement of the DPD, and post retrieval. Cinangiographic frames were counted from ostium of graft to distal anastomosis (TFCg), anastomosis to a standardized distal landmark (TFCn), and combined (TFC). Myocardial blush was graded 0-3 using the Zwolle/CRF methodology. Results: The two groups were balanced in demographics, risk factors, and clinical presentation. TIMI flows, frame counts, and blush are shown in Table. In-hospital non Qwave MI occurred in 5 pts in the filter group, and 1 in the balloon group (p=ns). There were no Q-wave MIs, urgent revascularizations, or mortality in either group. Conclusion: This early world experience in SVG's treatment suggests that balloon occlusion and aspiration DPD enhance immediate post procedure coronary flow (especially in the native coronary segment) and myocardial perfusion compared to filter-based DPDs. Whether this is due to learning curve with filters, or has clinical relevance deserves further study. Background: Endothelialization is essential to facilitate vessel healing after stent deployment to prevent restenosis. Circulating endothelial progenitor cells (EPC) are present in the peripheral blood and display endothelial functional properties along with ability to home to damaged vasculature. Prolific in-stent intimal growth may be related to impaired endothelialization resulting from a reduced number or dysfunction of circulating EPC. Methods: 27 patients (pts) after stent deployment had recurrent unstable angina and underwent coronary angiography. In 16 pts in-stent restenosis was demonstrated (group A), in 6 focal and in 10 diffuse. 11 had patent stents (group B). Both groups were similar with respect to drug usage and risk factors. Circulating EPC numbers were determined by the colony-forming unit assay and their phenotype was characterized by endothelialcell markers. Adhesiveness of EPC from both groups to extra-cellular matrix and to endothelial cells was also assayed. ). So far we identified an association between three polymorphism and TVR. The adrenergic beta-2 receptor and stromal cell derived factor (p=0.022, p=0.038 respectively) were associated with increased risk of TVR. Small inducible cytokine subfamily A (eotaxin) (p=0.057 ) showed a protective association with TVR. Conclusion: So far in this unselected large group of patients treated with PTCA, we already identified three polymorphisms in different candidate genes that were related to restenosis after PTCA. More genotyping is being performed. Our results can contribute to the unravelling of the restenotic process and might provide a better risk stratification and lead to a more tailored therapy for patients with identified increased risk of restenosis after PTCA. 
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